Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The German Patent Office has granted Alnylam Pharmaceuticals a patent that includes 52 claims broadly covering medicaments comprising of small interfering RNAs.
Subscribe to our email newsletter
The covered small interfering RNAs (siRNAs) are 15 to 49 nucleotide pairs in length. Alnylam said that the new Kreutzer-Limmer patent extends the worldwide scope for issued claims covering siRNA technology to Germany, the largest national pharmaceutical market of the European Union.
The patent series has been licensed to Alnylam’s four pharmaceutical collaboration partners, seven biotechnology companies in Alnylam’s InterfeRx program and 15 companies in the research reagent and services market. The patent is enforceable in Germany against potential infringers using the patented technology without an Alnylam license.
John Maraganore, president and CEO of Alnylam, said: “Our intellectual property estate for RNAi therapeutics remains unparalleled in the industry, and represents an important component of our efforts to bring our innovative medicines to patients.
“Importantly, the newly granted DE 10080167 patent covers a broad scope of medicaments containing siRNA structures having a length of 15 to 49 nucleotides which includes the so-called ‘blunt end’ or ‘dicer substrate’ design with or without chemical modifications, as well as other possible features.”